Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02924376 · OUTCOME

CL/F of Pemigatinib

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) · Source last updated 2025-08-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Liters/hour
Interval / dispersion
Standard Deviation
Time frame
Predose; 1-2 hours post-dose; 4-12 hours post-dose

What was measured

CL/F is defined as apparent oral clearance.

Analysis population: PK Population

Groups in this outcome

All Cohorts

Participants with FGFR2 rearrangements or fusions (Cohort A), participants with all other FGF/FGFR alterations (Cohort B), participants with no FGF/FGFR alterations (Cohort C; United States only), and participants with an FGF/FGFR status for whom the local laboratory FGF/FGFR results could not be confirmed centrally (Other) self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Cohorts136

Reported measurements

Source class 1
Values in Liters/hour · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
All Cohorts12.25.28Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        5.28
        value
        12.2
denoms
  1. counts
    1. group Id
      OG000
      value
      136
    units
    Participants
description
CL/F is defined as apparent oral clearance.
dispersion Type
Standard Deviation
groups
  1. description
    Participants with FGFR2 rearrangements or fusions (Cohort A), participants with all other FGF/FGFR alterations (Cohort B), participants with no FGF/FGFR alterations (Cohort C; United States only), and participants with an FGF/FGFR status for whom the local laboratory FGF/FGFR results could not be confirmed centrally (Other) self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.
    id
    OG000
    title
    All Cohorts
param Type
MEAN
population Description
PK Population
reporting Status
POSTED
time Frame
Predose; 1-2 hours post-dose; 4-12 hours post-dose
title
CL/F of Pemigatinib
type
SECONDARY
unit Of Measure
Liters/hour

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice